Can Immutep Limited convert orphan designation into a credible late-stage oncology program?
FDA orphan drug designation gives Immutep Limited a new sarcoma pathway. Find out why eftilagimod alfa could reshape its oncology strategy.
Pharma & Biotech
Pharma & Biotech
How the Lixte Biotechnology Holdings and dostarlimab study could influence future ovarian cancer trial design
Lixte Biotechnology’s LB-100 ovarian cancer data may signal a new immunotherapy pathway. Read what this could change for the sector.
Pharma & Biotech
What Oncolytics Biotech Inc.’s FDA meeting means for pelareorep commercialization
Can Oncolytics Biotech move pelareorep closer to approval in anal cancer? Read what the FDA meeting could change for clinicians and investors.
Pharma & Biotech
Can Calidi Biotherapeutics, Inc.’s RedTail platform solve the solid tumor T-cell engager problem?
Calidi Biotherapeutics, Inc. unveils new RedTail and TROP-2 data at AACR 2026. Read what this means for solid tumor immunotherapy and CLD-401 next.
Pharma & Biotech
How Agilent’s PD-L1 companion diagnostic now shapes pembrolizumab access in esophageal carcinoma
FDA approves Agilent's PD-L1 IHC 22C3 pharmDx for esophageal and GEJ carcinoma, marking the eighth companion diagnostic indication alongside pembrolizumab. Read the analysis.
Pharma & Biotech
IMUNON advances Phase 3 with stronger survival data, signaling a shift in ovarian cancer immunotherapy
IMNN-001 shows improved survival in ovarian cancer. Find out what this means for Phase 3 success and future treatment strategies.
Pharma & Biotech
OverT Bio moves OVT-101 closer to clinic as solid tumour cell therapy race intensifies
OverT Bio is advancing OVT-101 toward the clinic in ovarian cancer. Read what its new advisory board could change for solid tumour cell therapy.
Pharma & Biotech
Curatis licenses corticorelin to Neupharma in CHF 83.5m Japan deal
Curatis and Neupharma sign a CHF 83.5m Japan licensing deal for corticorelin in peritumoral brain edema. Read our analysis of what the deal means.
Pharma & Biotech
What PolTREG-T1D reveals about the future of cell therapy in autoimmune diseases
PolTREG advances its TREG cell therapy for type 1 diabetes toward EU approval. Learn what this milestone means for autoimmune disease treatment.
Pharma & Biotech
How Citius Oncology’s LYMPHIR program reflects a broader shift in immuno-oncology strategy
Citius Oncology reports early LYMPHIR plus pembrolizumab data in gynecologic cancers. Explore what the study reveals about the future of immuno-oncology strategies.